ABIOMED, Inc.
May 4, 2017
PDF

Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year

 

DANVERS, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2017 revenue of $124.7 million, an increase of 33% compared to revenue of $94.0 million for the same period of fiscal 2016.  For fiscal year 2017, total revenue was $445.3 million, up 35% compared to revenue of $329.5 million in fiscal year 2016.

Fourth quarter fiscal 2017 GAAP net income was $14.9 million or $0.33 per diluted share, impacted by $3.1 million or $0.07 per diluted share of one-time items, described below. For the full fiscal year, GAAP net income was $52.1 million or $1.17 per diluted share.

Financial and operating highlights during the fourth quarter of fiscal 2017 include:

"Abiomed remains one of the fastest growing GAAP profitable companies and fiscal 2017 was another successful year as we achieved our corporate goals with two FDA approvals, approval in Japan, and dedicated DRGs from the Centers for Medicare and Medicaid Services (CMS)," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "We want to thank our shareholders for their support and all of our employees and customers for their hard work and dedication to patients and our mission of heart recovery."

FISCAL YEAR 2018 OUTLOOK
The Company is giving its fiscal year 2018 guidance for total revenues to be in the range of $555 million to $575 million, an increase of 25% - 29% over the prior year. The Company is also giving its fiscal year 2018 guidance for GAAP operating margin to be in the range of 22% to 24%.

EARNINGS CONFERENCE CALL DETAILS
The Company will host a conference call to discuss the results at 8 a.m. ET on Thursday, May 4, 2017. The conference call releasing full quarterly results will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Michael Tomsicek, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EDT May 4, 2017 through 11:00 a.m. EDT on May 7, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 3991529.

The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella CP, Impella 5.0, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries. cVAD Registry is a trademark of ABIOMED, Inc.

ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS 
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 

Abiomed, Inc. and Subsidiaries  
Consolidated Balance Sheets  
(Unaudited)  
(in thousands, except share data)  
           
    March 31, 2017   March 31, 2016  
           
ASSETS          
Current assets:          
Cash and cash equivalents   $   39,040     $   48,231    
Short-term marketable securities       190,908         163,822    
Accounts receivable, net        54,055         42,821    
Inventories        34,931         26,740    
Prepaid expenses and other current assets       8,024         6,778    
Total current assets       326,958         288,392    
Long-term marketable securities       47,143         1,000    
Property and equipment, net       87,777         23,184    
Goodwill       31,045         33,003    
In-process research and development       14,482         15,396    
Long-term deferred tax assets, net       34,723         58,534    
Other assets       8,286         4,422    
Total assets   $   550,414     $   423,931    
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable   $   20,620     $   9,381    
Accrued expenses       37,703         28,382    
Deferred revenue       10,495         8,778    
Current portion of capital lease obligation       799         —    
Total current liabilities       69,617         46,541    
Other long-term liabilities       3,251         220    
Contingent consideration       9,153         7,563    
Long-term deferred tax liabilities       783         832    
Capital lease obligation, net of current portion       15,539         —    
Total liabilities       98,343         55,156    
Commitments and contingencies          
Stockholders' equity:          
Class B Preferred Stock, $.01 par value       —         —    
Authorized - 1,000,000 shares; Issued and outstanding - none          
Common stock, $.01 par value       437         426    
Authorized - 100,000,000 shares; Issued - 45,249,281 shares at March 31, 2017 and 43,973,119 shares at March 31, 2016;          
Outstanding - 43,673,286 shares at March 31, 2017 and 42,596,228 shares at March 31, 2016          
Additional paid in capital       565,962         508,624    
Accumulated deficit       (46,959 )       (99,075 )  
Treasury stock at cost - 1,575,995 shares at March 31, 2017 and 1,376,891 shares at March 31, 2016       (46,763 )       (26,660 )  
Accumulated other comprehensive loss       (20,606 )       (14,540 )  
Total stockholders' equity       452,071         368,775    
Total liabilities and stockholders' equity   $   550,414     $   423,931    
           

 

Abiomed, Inc. and Subsidiaries  
Consolidated Statements of Operations  
(Unaudited)  
(in thousands, except per share data)  
                         
                         
  Three Months Ended
March 31,
  Fiscal Years Ended
March 31,
 
  2017     2016   2017     2016  
Revenue:                        
Product revenue $ 124,654     $ 93,951   $ 445,195     $ 329,520  
Funded research and development   26       6     109       23  
    124,680       93,957     445,304       329,543  
Costs and expenses:                        
Cost of product revenue    19,261       14,663     70,627       50,419  
Research and development    16,325       14,225     66,386       49,759  
Selling, general and administrative    60,100       45,256     218,153       164,261  
    95,686       74,144     355,166       264,439  
Income from operations   28,994       19,813     90,138       65,104  
Other income:                        
Investment income, net   486       186     1,554       395  
Other (expense) income, net   (124 )     228     (349 )     339  
    362       414     1,205       734  
Income before income taxes   29,356       20,227     91,343       65,838  
Income tax provision   14,457       9,229     39,227       27,691  
Net income $ 14,899     $ 10,998   $ 52,116     $ 38,147  
                         
Basic net income per share $ 0.34     $ 0.26   $ 1.21     $ 0.90  
Basic weighted average shares outstanding   43,579       42,463     43,238       42,204  
                         
Diluted net income per share $ 0.33     $ 0.24   $ 1.17     $ 0.85  
Diluted weighted average shares outstanding   44,924       45,112     44,658       44,895  
                         

 

For further information please contact: 

Ingrid Goldberg,
Director, Investor Relations
978-646-1590
ir@abiomed.com

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com